The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613 - Concepedia

Concepedia

Publication | Open Access

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613

DOI Full Paper Access

96

Citations

29

References

2017

Year

Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eléonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse,

Clinical Lung Cancer

References

	Year	Citations

Page 1